Ceribell

Ceribell Financial Leverage

The Financial Leverage (Equity Multiplier) of Ceribell (CBLL) as of Nov 20, 2026 is 1.26. In the previous year, Financial Leverage (Equity Multiplier) was 1.18 — a change of 6.90% (higher).

Financial Leverage

1.26

YoY

6.90%

Last updated:

Financial Leverage (Equity Multiplier) of Ceribell is 2025 1.26 . Financial Leverage (Equity Multiplier) of Ceribell was 2024 1.18 . It decreases by 6.90% higher compared to the previous year.

The Ceribell Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
-1.00 USD
Jan 1, 2023
-0.52 USD
Jan 1, 2024
1.18 USD
Jan 1, 2025
1.26 USD
The Ceribell Financial Leverage history
YEARFinancial LeverageYoY
1.26+6.90%
1.18-324.64%
-0.52-47.55%
-1.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ceribell Stock analysis

What does Ceribell do? Ceribell, Inc. generates revenue through its Ceribell System, a point-of-care EEG platform designed for acute care settings. The system combines portable hardware with AI-powered algorithms, including the Clarity AI algorithm that provides real-time EEG interpretation, bedside alerts, and continuous monitoring for status epilepticus. Hospitals and healthcare providers purchase the Ceribell System to improve neurological diagnosis and management, particularly for patients with acute conditions requiring rapid seizure detection. The Ceribell EEG Portal is also offered as part of the solution to facilitate data access and management. The company's primary customers are healthcare institutions seeking to enhance patient care efficiency through advanced neurological monitoring. By enabling early detection and continuous monitoring, the Ceribell System supports precise treatment decisions and reduces hospital resource strain. The Clarity AI algorithm is a key differentiator, delivering real-time insights that address critical unmet needs in acute neurological care. Ceribell, Inc. focuses on transforming diagnosis and management of serious neurological conditions through its proprietary technology. The Ceribell System's portability and rapid deployment make it suitable for acute care environments where timely intervention is crucial. Healthcare providers use the system to monitor patients with suspected seizures, leveraging the AI-driven insights for immediate clinical action. Ceribell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ceribell stock

Financial Leverage (Equity Multiplier) of Ceribell is 1.26 in 2025.

Financial Leverage (Equity Multiplier) of Ceribell changed from 1.18 to 1.26, representing a 6.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Ceribell since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Ceribell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ceribell

All Key Metrics — Ceribell